Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Roivant Sciences Ltd (ROIV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ROIV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $17.11
1 Year Target Price $17.11
| 6 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.25% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.02B USD | Price to earnings Ratio - | 1Y Target Price 17.11 |
Price to earnings Ratio - | 1Y Target Price 17.11 | ||
Volume (30-day avg) 10 | Beta 1.15 | 52 Weeks Range 8.73 - 13.05 | Updated Date 08/15/2025 |
52 Weeks Range 8.73 - 13.05 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When Before Market | Estimate -0.2462 | Actual -0.2501 |
Profitability
Profit Margin - | Operating Margin (TTM) -13130.05% |
Management Effectiveness
Return on Assets (TTM) -10.73% | Return on Equity (TTM) -12.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3620403480 | Price to Sales(TTM) 345.36 |
Enterprise Value 3620403480 | Price to Sales(TTM) 345.36 | ||
Enterprise Value to Revenue 155.83 | Enterprise Value to EBITDA 0.74 | Shares Outstanding 682881984 | Shares Floating 400093064 |
Shares Outstanding 682881984 | Shares Floating 400093064 | ||
Percent Insiders 26.39 | Percent Institutions 82.21 |
Upturn AI SWOT
Roivant Sciences Ltd
Company Overview
History and Background
Roivant Sciences was founded in 2014 by Vivek Ramaswamy. Its initial focus was on acquiring and developing potentially promising drugs that had been shelved by larger pharmaceutical companies. Roivant operates as a parent company to multiple 'Vant' companies, each focused on a specific therapeutic area.
Core Business Areas
- Drug Development: Roivant acquires and develops pharmaceutical products across various therapeutic areas.
- Vant Platform: Roivant creates and manages a platform of Vant companies that operate independently but benefit from Roivant's centralized resources and expertise.
- Technology Platform: Roivant utilizes technology to improve drug development and commercialization processes.
Leadership and Structure
Matt Gline is the Chief Executive Officer. The company operates through a decentralized structure of 'Vant' companies, each with its own leadership team.
Top Products and Market Share
Key Offerings
- VTAMA (tapinarof): A topical cream for the treatment of plaque psoriasis in adults. Market share data is unavailable, but it competes with other topical corticosteroids and vitamin D analogs. Competitors include companies like LEO Pharma, and Amgen with Otezla. Revenue is steadily increasing but varies by quarter.
- RVT-3101 (TL1A Inhibitor): An investigational monoclonal antibody being developed for the treatment of ulcerative colitis and Crohn's disease. It's in clinical development, so market share is not yet applicable. Potential competitors include TNF inhibitors (e.g., Humira, Remicade) and other emerging therapies in the inflammatory bowel disease space.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and subject to extensive regulation. It is characterized by high R&D costs, long development timelines, and patent protection for innovative products.
Positioning
Roivant positions itself as a disrupter in the pharmaceutical industry, leveraging its platform approach and technology to improve drug development efficiency. Its competitive advantage lies in its ability to identify undervalued assets and accelerate their development.
Total Addressable Market (TAM)
The total addressable market varies depending on the specific therapeutic areas Roivant is targeting. For example, the psoriasis market is estimated to be in the billions of dollars. Roivant aims to capture a significant share of these markets through its innovative products and strategies.
Upturn SWOT Analysis
Strengths
- Decentralized 'Vant' structure
- Strong financial backing
- Experienced management team
- Focus on undervalued assets
- Technological innovation in drug development
Weaknesses
- Dependence on successful drug development
- High R&D expenses
- Potential for regulatory setbacks
- Limited commercialization experience compared to larger pharma companies
Opportunities
- Acquisition of additional undervalued assets
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Continued development of innovative technologies
Threats
- Competition from established pharmaceutical companies
- Patent expirations
- Changes in regulatory landscape
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- BMY
- PFE
- MRK
Competitive Landscape
Roivant faces competition from both large pharmaceutical companies and smaller biotech firms. Its competitive advantage lies in its platform approach and focus on undervalued assets, but it faces challenges in terms of commercialization experience and financial resources compared to larger competitors.
Major Acquisitions
Silicon Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 450
- Strategic Rationale: To enhance Roivant's drug discovery capabilities through Silicon Therapeutics' physics-based computational platform.
Growth Trajectory and Initiatives
Historical Growth: Roivant's historical growth has been driven by its ability to acquire and develop promising drug candidates. The company has also expanded its platform through the creation of new 'Vant' companies.
Future Projections: Future growth projections depend on the successful development and commercialization of its pipeline products, as well as strategic partnerships and acquisitions. Analyst estimates vary based on individual product potential and market conditions.
Recent Initiatives: Recent initiatives include advancing clinical trials for key drug candidates, expanding partnerships with other companies, and leveraging technology to improve drug development efficiency.
Summary
Roivant Sciences is a biotech company with a unique business model, developing promising therapies and leveraging its 'Vant' platform. While its decentralized approach and focus on undervalued assets are strengths, it faces challenges related to drug development risks and competition. The company's success hinges on advancing its pipeline and capitalizing on strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Roivant Sciences Ltd. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data is approximate and may vary by source. Financial data is subject to change based on future performance and market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Roivant Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-10-01 | CEO & Director Mr. Matthew Gline | ||
Sector Healthcare | Industry Biotechnology | Full time employees 750 | Website https://roivant.com |
Full time employees 750 | Website https://roivant.com | ||
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.